David F. Penson

Side effects of modern PCa treatments comparedDespite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.
Off the fee-for-service hamster wheel
AUA, others continue blitz on USPSTF reformThe AUA and other organizations have been urging Congress to create transparency and accountability within the USPSTF while adding input and feedback from patients and specialists involved in treating the conditions for which it is developing recommendations.
Collaboration urged in managing ADT-related CV riskPhysicians at Vanderbilt University Medical Center, Nashville, have opened a dedicated cardio-oncology service, including urology, medical oncology, radiation oncology, and cardiology.
MOC, ICD-10 among hot urology topics of 2015Look back on the year that was with this roundup of the 10 most-read Urology Times articles from 2015.
AUA, others fight measure penalizing docs who order PSAThe proposed clinical quality measure comes as a pair of JAMA studies note a decline in screening since the USPSTF recommended against screening.
How much does treating low-risk PCa really cost?Researchers say they’ve uncovered a wide variation in costs to treat low-risk prostate cancer.
ACA, MACRA: What they mean for you, patientsIn this interview, David F. Penson, MD, MPH, discusses the ACA’s impact on urology, the pros and cons of a single-payer system, and why collecting and reporting outcomes data will be crucial going forward.
Androgen receptor inhibitor shows significant PFS increase
Androgen receptor inhibitor shows significant PFS increaseRecent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).
Urology groups reiterate support for USPSTF billThe major organizations representing urologists are continuing their push for congressional approval of legislation designed to reform the operations of the U.S. Preventive Services Task Force, which in May 2012 recommended against PSA-based screening for prostate cancer.